The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices is evaluating whether to recommend GlaxoSmithKline plc’s blockbuster shingles vaccine Shingrix for use in immunocompromised adults 19 years of age and older, which would expand its availability to millions of additional people.
At ACIP’s 25 June meeting, ACIP’s herpes zoster work group reported its initial discussions on use of Shingrix (zoster vaccine,...





